BIT:1EXAS - US30063P1057 - Common Stock
The current stock price of 1EXAS.MI is 38.5 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 19.71 | 314.80B | ||
1ABBV.MI | ABBVIE INC | 19.67 | 314.07B | ||
AMG.DE | AMGEN INC | 13.25 | 132.79B | ||
1GILD.MI | GILEAD SCIENCES INC | 14.85 | 122.10B | ||
GIS.DE | GILEAD SCIENCES INC | 14.56 | 119.45B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 22.85 | 84.72B | ||
ARGX.BR | ARGENX SE | 82.33 | 37.19B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 20.79B | ||
IDP.DE | BIOGEN INC | 8.41 | 16.85B | ||
1MRNA.MI | MODERNA INC | N/A | 8.13B | ||
0QF.DE | MODERNA INC | N/A | 8.09B | ||
ABVX.PA | ABIVAX SA | N/A | 5.22B |
EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,900 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
EXACT SCIENCES CORP
5505 Endeavor Lane
Madison WISCONSIN US
Employees: 6900
Phone: 16082845700
The current stock price of 1EXAS.MI is 38.5 EUR. The price decreased by -3.01% in the last trading session.
The exchange symbol of EXACT SCIENCES CORP is 1EXAS and it is listed on the Euronext Milan exchange.
1EXAS.MI stock is listed on the Euronext Milan exchange.
EXACT SCIENCES CORP (1EXAS.MI) has a market capitalization of 7.29B EUR. This makes 1EXAS.MI a Mid Cap stock.
EXACT SCIENCES CORP (1EXAS.MI) currently has 6900 employees.
The Revenue of EXACT SCIENCES CORP (1EXAS.MI) is expected to grow by 14.7% in the next year. Check the estimates tab for more information on the 1EXAS.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
1EXAS.MI does not pay a dividend.
EXACT SCIENCES CORP (1EXAS.MI) will report earnings on 2025-11-03, after the market close.
EXACT SCIENCES CORP (1EXAS.MI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.64).
ChartMill assigns a technical rating of 1 / 10 to 1EXAS.MI.
ChartMill assigns a fundamental rating of 3 / 10 to 1EXAS.MI. The financial health of 1EXAS.MI is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months 1EXAS.MI reported a non-GAAP Earnings per Share(EPS) of -4.64. The EPS decreased by -465.62% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -17.34% | ||
ROE | -40.71% | ||
Debt/Equity | 0.94 |
For the next year, analysts expect an EPS growth of 89.28% and a revenue growth 14.7% for 1EXAS.MI